Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a report issued on Sunday morning.

A number of other equities research analysts have also weighed in on MNPR. BTIG Research boosted their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Barclays restated an “overweight” rating and set a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday, August 13th. HC Wainwright upped their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

Monopar Therapeutics Stock Up 2.2%

Shares of MNPR stock opened at $119.05 on Friday. The company has a 50 day moving average price of $98.39 and a 200-day moving average price of $72.22. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $124.82. The firm has a market capitalization of $798.83 million, a PE ratio of -54.86 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. Analysts anticipate that Monopar Therapeutics will post -2.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in Monopar Therapeutics in the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. boosted its holdings in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics during the 2nd quarter valued at about $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.